DE69021761T2 - Impfstoff gegen Tinea. - Google Patents

Impfstoff gegen Tinea.

Info

Publication number
DE69021761T2
DE69021761T2 DE69021761T DE69021761T DE69021761T2 DE 69021761 T2 DE69021761 T2 DE 69021761T2 DE 69021761 T DE69021761 T DE 69021761T DE 69021761 T DE69021761 T DE 69021761T DE 69021761 T2 DE69021761 T2 DE 69021761T2
Authority
DE
Germany
Prior art keywords
tinea
vaccine
tinea vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69021761T
Other languages
English (en)
Other versions
DE69021761D1 (de
DE69021761T3 (de
Inventor
Mark Werner
Michael Strobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jefferson Labs Inc
Original Assignee
Jefferson Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23339353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69021761(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jefferson Labs Inc filed Critical Jefferson Labs Inc
Publication of DE69021761D1 publication Critical patent/DE69021761D1/de
Publication of DE69021761T2 publication Critical patent/DE69021761T2/de
Application granted granted Critical
Publication of DE69021761T3 publication Critical patent/DE69021761T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE1990621761 1989-04-21 1990-03-21 Impfstoff gegen Tinea. Expired - Lifetime DE69021761T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34186789A 1989-04-21 1989-04-21
US341867 1989-04-21

Publications (3)

Publication Number Publication Date
DE69021761D1 DE69021761D1 (de) 1995-09-28
DE69021761T2 true DE69021761T2 (de) 1996-02-15
DE69021761T3 DE69021761T3 (de) 2005-01-13

Family

ID=23339353

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1990621761 Expired - Lifetime DE69021761T3 (de) 1989-04-21 1990-03-21 Impfstoff gegen Tinea.

Country Status (5)

Country Link
US (6) US5453273A (de)
EP (1) EP0393371B2 (de)
JP (1) JP2972274B2 (de)
CA (1) CA2011896C (de)
DE (1) DE69021761T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011896C (en) 1989-04-21 2001-05-08 Mark Werner Ringworm vaccine
RU2020959C1 (ru) * 1991-10-21 1994-10-15 Игорь Дмитриевич Поляков Вакцина поливак-тм для профилактики и лечения дерматофитозов животных
US6720576B1 (en) * 1992-09-11 2004-04-13 Semiconductor Energy Laboratory Co., Ltd. Plasma processing method and photoelectric conversion device
DK0757556T3 (da) * 1994-04-11 2006-10-02 Wyeth Corp Borrelia Burgdorferi-bakterin
EP0834322A3 (de) 1996-10-04 1998-04-22 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Vakzine zur Behandlung von Mycosen
AU2232399A (en) * 1998-01-16 1999-08-02 Maxim Pharmaceuticals, Inc. Recombinant ctb-based vaccines
CZ20012732A3 (cs) * 2001-07-27 2002-08-14 Bioveta, A.S. Vakcína proti dermatofytózám a způsob její výroby
WO2003018051A1 (en) * 2001-08-27 2003-03-06 Vic Jira Anti-fungal composition
EP1765313A2 (de) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Verbindungen als immunstimulatoren
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
AU2017234985B2 (en) 2016-03-15 2023-10-12 Liudmila IVANOVA Compositions for the treatment and prevention of hoof and claw diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2011225A (en) * 1933-03-16 1935-08-13 Krueger Albert Paul Antigen and process of producing it
US3897550A (en) * 1971-06-01 1975-07-29 Cybersol Method for administering water soluble drugs, nutrients and other solutes to a mammal
GB1548436A (en) * 1976-10-19 1979-07-18 Inst Experimentalnoi Veterinar Vaccine for phophylaxis of trichaphytosis in the horse andmethod of preparing same
NO153458C (no) * 1978-06-07 1986-03-26 Inst Experimentalnoi Veterinar Fremgangsm¨te for fremstilling av vaksine for profylakse o g behandling av ringorm hos pelsdyr og kaniner for¨rsaket av trichophyton mentagrophytes.
SU1734762A1 (ru) * 1989-01-26 1992-05-23 Всесоюзный Научно-Исследовательский Институт Экспериментальной Ветеринарии Им.Я.Р.Коваленко Способ изготовлени вакцины дл профилактики дерматофитозов домашних и лабораторных животных
CA2011896C (en) * 1989-04-21 2001-05-08 Mark Werner Ringworm vaccine
US5277904A (en) * 1990-10-26 1994-01-11 Pier Allan C Broad spectrum dermatophyte vaccine
EP0627936A4 (de) * 1992-02-18 1997-01-02 Parhelion Corp Impfstoff gegen die infektiöse peritonitis bei katzen und methode seiner herstellung.

Also Published As

Publication number Publication date
US7258866B2 (en) 2007-08-21
JPH03128328A (ja) 1991-05-31
US20020187155A1 (en) 2002-12-12
US5453273A (en) 1995-09-26
US6132733A (en) 2000-10-17
US6428789B1 (en) 2002-08-06
EP0393371A1 (de) 1990-10-24
US20080050405A1 (en) 2008-02-28
EP0393371B1 (de) 1995-08-23
JP2972274B2 (ja) 1999-11-08
DE69021761D1 (de) 1995-09-28
CA2011896C (en) 2001-05-08
DE69021761T3 (de) 2005-01-13
EP0393371B2 (de) 2004-04-14
US20060147475A1 (en) 2006-07-06
CA2011896A1 (en) 1990-10-21
US6723328B2 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
FI903382A0 (fi) Topiskt anbringbara farmaceutiska preparat.
FI906367A0 (fi) Terapeutiska nukleosider.
FI913899A0 (fi) Terapeutiska aerosolblandningar.
FI902502A0 (fi) Ampull.
DK272889A (da) Vaccine
DE69006406D1 (de) Brennerstein-Aufbau.
DE69005622D1 (de) Motorisierte gehhilfe.
DK189788D0 (da) Vaccine
DE3882781D1 (de) Impfstoff gegen pasteurella.
DE69021761D1 (de) Impfstoff gegen Tinea.
FI904854A0 (fi) Terapeutiska nukleosider.
DE69026975D1 (de) Impfstoff gegen Coccidiosis
NO900493L (no) Dobbeltdoer-anordning.
NO875038D0 (no) Konjugert vaksine.
DE69020848D1 (de) Impfstoff gegen IBV.
NO900442L (no) Vaksineblanding.
DE69014974D1 (de) Impfstoff gegen Hundecoronavirus.
DE69013586T2 (de) Rollstuhl.
DE59003439D1 (de) Grubber.
DE68927340T2 (de) Biologischer impfstoff, wirksam gegen aphanomyces
DE68918189D1 (de) Neisseria-Vakzine.
DE69000980T2 (de) Rollstuhl.
DE68910125T2 (de) Oral-Präparate.
NO901959D0 (no) Malaria-vaksine.
ATE144103T1 (de) Biologischer impfstoff, wirksam gegen aphanomyces

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings